GlassScriptPhysician profile
Mitchell L Cassel
NPI 1336217827
$8,938.63
in general payments reported to CMS, 2019-2025
12 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,029 · 2020: $96.45 · 2021: $624 · 2022: $651 · 2023: $820 · 2024: $887 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482 · Travel and Lodging: $1,049 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.87 |
| Travel and Lodging | $1,048.87 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,227.37 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $2,836.74 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $242.27 | 2024-2025 | Xdemvy |
| Coopervision INC. | $122.66 | 2022-2023 | Myday Contact Lens |
| Allergan, INC. | $120.53 | 2021 | |
| Bausch & Lomb Americas INC. | $116.31 | 2023-2025 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $76.74 | 2022-2023 | Cequa |
| Topcon Healthcare, INC. | $69.73 | 2019 | |
| Abbvie INC. | $45.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.55 | 2021-2022 | |
| Oyster Point Pharma, INC. | $27.30 | 2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $23.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Cassel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.